Land: Malta
Tungumál: enska
Heimild: Medicines Authority
atovaquone 62.5 mg, proguanil hydrochloride 25 mg
1 A Pharma GmbH
P01BB51
atovaquone, proguanil hydrochloride
film-coated tablet
Authorised
2013-06-25
Page 1 of 7 PACKAGE LEAFLET: INFORMATION FOR THE USER REPRAPOG 62.5 MG/25 MG FILM-COATED TABLETS atovaquone/proguanil hydrochloride READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE, BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Reprapog is and what it is used for 2. What you need to know before you give Reprapog 3. How to give Reprapog 4. Possible side effects 5. How to store Reprapog 6. Contents of the pack and other information 1. WHAT REPRAPOG IS AND WHAT IT IS USED FOR Reprapog belongs to a group of medicines called antimalarials. It contains two active ingredients, atovaquone and proguanil hydrochloride. Reprapog has two uses: • to prevent malaria (for children and adults weighing between 11 kg and 40 kg) • to treat malaria (for children weighing between 5 kg and 11 kg) Although this medicine is usually used for children and teenagers, it can be prescribed for adults weighing less than 40 kg. Malaria is spread by the bite of an infected mosquito, which passes the malaria parasite (Plasmodium falciparum) into the bloodstream. Reprapog prevents malaria by killing this parasite. For people who are already infected with malaria, Reprapog also kills these parasites. _Protect your child from catching malaria _ People of Lestu allt skjalið
Page 1 of 13 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Reprapog 62.5 mg/25 mg film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: 62.5 mg atovaquone and 25 mg proguanil hydrochloride For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet. Pink, round, biconvex film coated tablets debossed with 'I' on one side and '11' on the other side. Thickness of the tablet is 3.00 mm (± 0.30) and diameter 7.40 mm (± 0.20). 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Prophylaxis of _Plasmodium falciparum_ malaria in adults and children weighing 11-40 kg. Treatment of acute, uncomplicated _Plasmodium falciparum_ malaria in children weighing ≥5 kg and <11 kg. Official guidelines and local information on the prevalence of resistance to antimalarial drugs should be taken into consideration. Official guidelines will normally include WHO and public health authorities‘ guidelines. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The dosage for the prophylaxis and treatment of acute, uncomplicated _P. falciparum_ malaria in children is based on body weight. PROPHYLAXIS _Dosage in adults and children weighing 11-40 kg _ DOSAGE/DAY BODY WEIGHT RANGE (KG) ATOVAQUONE (MG) PROGUANIL (MG) NO OF TABLETS 11-20 62.5 25 One Reprapog tablet 21-30 125 50 Two Reprapog tablets 31-40 187.5 75 Three Reprapog tablets >40 250 100 Subjects of >40 kg should Page 2 of 13 receive ONE tablet daily containing 250 mg atovaquone and 100 mg proguanil hydrochloride. The safety and effectiveness of atovaquone/proguanil for prophylaxis of malaria in children who weigh less than 11 kg has not been establ Lestu allt skjalið